BUZZ-GRI Bio jumps as experimental lung drug shows promise in mid-stage trial** Shares of drug developer GRI Bio GRI.O rise 18% to $1.43 in after-hours trading
** Co says its experimental drug, GRI-0621, showed promising results in a mid-stage clinical trial for idiopathic pulmonary fibrosis
** IPF is a chronic lung disease with limited treatment options, co says
** Nearly 40% of treated patients saw better lung capacity vs 80% decline on placebo — GRI
** Trial enrolled 35 patients, most on existing IPF drugs; blood tests suggest reduced lung scarring — GRI
** Including session's move, stock down ~91% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.